MCCULLOCH KEVIN enters XERIS BIOPHARMA HOLDINGS, INC. with 1.48M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Indirect Derivatives
Filed: 8/2/2024ACC: 0001867096-24-000141
Officer· See Remarks
Since Mar 2026
1.48M
Baseline shares
98% direct
1.45M
Direct ownership
1 position
172.67K
Derivative underlying
2 instruments
3
Security positions
27K indirect
Non-Derivative Holdings3
Common Stock
DirectShares owned1.45M
Common Stock
IndirectShares owned2K
Common Stock
IndirectShares owned25K
Total
1.45M direct·27K indirect1.48M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.45M | Direct |
| Common Stock | 2K | Indirect |
| Common Stock | 25K | Indirect |
| Total | 1.48M | 1.45M direct·27K indirect |
Derivative Holdings2
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
80K
Shares owned
N/A
Exercise price
3.94
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
92.67K
Shares owned
N/A
Exercise price
4.09
Expiration
—
Exercise window
—
Total
Underlying
172.67K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 3.94 | — | — | 80K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 4.09 | — | — | 92.67K | N/A |
| Total | 172.67K | 0.00 | ||||